Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-07-31), the Forward Annual Dividend Yield of Ocumension Therapeutics is 0.00%.
As of today (2026-07-31), the Trailing Annual Dividend Yield of Ocumension Therapeutics is 0.00%.
FRA:5DG's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.35 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Ocumension Therapeutics Forward Dividend Yield % Related Terms
FRA:5DG vs VRTX, REGN, RVMD: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Ocumension Therapeutics (FRA:5DG) has a Forward Dividend Yield % of 0.00% as of Jul. 31, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Ocumension Therapeutics and its competitors. According to the industry distribution chart, Ocumension Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry.
Is Ocumension Therapeutics' Forward Dividend Yield % too high?
Ocumension Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Ocumension Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ocumension Therapeutics has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Ocumension Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.35, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Ocumension Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (FRA:5DG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.04, compared to a current price of €0.53 — trading 74.3% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Ocumension Therapeutics' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Ocumension Therapeutics (FRA:5DG), the current Forward Dividend Yield % is 0.00% as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (FRA:5DG) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of €0.53 is trading 74.3% below its estimated GF Value™ of €2.04.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:5DG:
Forward Dividend Yield %: 0.00%
GF Value™: €2.04 vs. price of €0.53 (74.3% below fair value)
No single metric tells the full story. See the FRA:5DG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
65GF Score
Get the complete analysis for FRA:5DG
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5DG has been successfully added to your 
